Sunho Biologics, Inc. (SUNHO BIO-B) reported that its share capital structure was unchanged for the month ended 31 July 2026, according to the company’s monthly return filed with Hong Kong Exchanges and Clearing Ltd. on 5 August 2026.

• Authorised share capital stayed at 200.00 million ordinary shares with a par value of USD 0.0005, equivalent to USD 100,000.

• Issued share capital remained at 156.67 million ordinary shares. The company held no treasury shares at either the beginning or end of the month, and there were no new issues, cancellations, or repurchases.

• Sunho Biologics confirmed compliance with the Main Board’s minimum public float requirement of 25 percent for the reporting period.

• The filing recorded no outstanding share options, warrants, convertible securities, or other arrangements that could dilute existing shareholders.

Chairman and Executive Director Zhang Feng signed the return, reaffirming that the disclosed figures accurately reflect the company’s capital position as of 31 July 2026.